Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04854304 · ClinicalTrials.gov registry record
Abbreviate or FAST Breast MRI for Supplemental Breast Cancer Screening for Black Women at Average Risk and Dense Breasts
A clinical trial of Breast Diseases, sponsored by Abramson Cancer Center at Penn Medicine.
- Active
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT04854304: Active study of Breast Diseases, sponsored by Abramson Cancer Center at Penn Medicine.
NCT04854304 is a study of Breast Diseases that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 500 participants, above the 255-participant average among 8 other Breast Diseases trials with a reported enrollment target (96% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04854304, a study of Breast Diseases, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
500 patients will be prospectively recruited to undergo a fast breast MRI examination. The women will be recruited for the study will meet the following criteria: 1. African American 2. negative DBT examination 11 months prior to recruitment 3. Heterogeneously and Extremely breast densities 4. clinically asymptomatic- no palpable masses, focal thickening or clinically significant discharge. Investigators will identify these patients EPIC database utilizing the date of their last mammogram. Interested patients may contact our research coordinators by the phone number provided in the recruitment materials. The study recruitment information will also be shared with referring physicians. Physicians may also directly refer patients to the study.
Primary Outcome
The cancer detection and false negative rate (per 1000 women screened) of supplemental screening with AB-MR in this population will be measured as well as the stage, grade and subtype of detected and non-detected breast cancers.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Fast Breast Abbreviated Magnetic Renounce Imaging
Study Locations (1)
Pennsylvania
- UPENN - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2021-09-23 |
| Est. Completion | 2028-07-13 |
What the registry record for NCT04854304 still lists
NCT04854304 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 255-participant average among 8 other Breast Diseases trials with a reported enrollment target (96% higher).
The record links to 1 condition, with Breast Diseases appearing as the primary indexed condition, and to 1 intervention - of which Fast Breast Abbreviated Magnetic Renounce Imaging is the first listed.
NCT04854304 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04854304 about?
NCT04854304 is a clinical study titled "Abbreviate or FAST Breast MRI for Supplemental Breast Cancer Screening for Black Women at Average Risk and Dense Breasts". 500 patients will be prospectively recruited to undergo a fast breast MRI examination. The women will be recruited for the study will meet the following criteria: 1. African American 2. negative DBT examination 11 months prior to recruitment 3. Heterogeneously and Extremely breast densities 4. clini...
What is the current status of trial NCT04854304?
This trial is currently active not recruiting. The enrollment target is 500 participants. The study started on 2021-09-23. Estimated completion is 2028-07-13.
What conditions does trial NCT04854304 study?
This clinical trial studies the following conditions: Breast Diseases.
What interventions are being tested in trial NCT04854304?
The interventions under investigation include: Fast Breast Abbreviated Magnetic Renounce Imaging (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04854304?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04854304 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04854304's enrollment target sits among peer trials
500 3rd of 8 higher than 6 of 8 other Breast Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
RECRUITING · Phase 1
-
A Study of Breast Cancer Risk Factors and Outcomes of People in Florida
RECRUITING
-
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation
ACTIVE NOT RECRUITING · Phase 3
-
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
ACTIVE NOT RECRUITING · Phase 1
-
Lesion Detection of Automated Breast Ultrasound Compared With Handheld Physician-performed Breast Ultrasound
COMPLETED · NA
-
Dotarem vs Gadobutrol Contrast for Breast MRI
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI